Teva Pharmaceutical Industries ADR (TEVA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2013 | 03-2013 | 12-2012 | 09-2012 | 06-2012 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 170,000 | 626,000 | 1,910,000 | 1,630,000 | 1,714,000 |
| Depreciation Amortization | 787,000 | 387,000 | 1,708,000 | 1,315,000 | 903,000 |
| Income taxes - deferred | -437,000 | -100,000 | -690,000 | -503,000 | -311,000 |
| Other Working Capital | 1,210,000 | 60,000 | 414,000 | -34,000 | -456,000 |
| Other Operating Activity | 247,000 | 129,000 | 1,230,000 | 587,000 | 97,000 |
| Operating Cash Flow | $1,977,000 | $1,102,000 | $4,572,000 | $2,995,000 | $1,947,000 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -339,000 | -121,000 | -840,000 | -577,000 | -395,000 |
| Purchase Of Investment | -113,000 | -104,000 | -201,000 | -73,000 | -25,000 |
| Other Investing Activity | -80,000 | -41,000 | -93,000 | -75,000 | -56,000 |
| Investing Cash Flow | $-532,000 | $-266,000 | $-1,134,000 | $-725,000 | $-476,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 5,000 | -20,000 | -2,492,000 | -2,514,000 | -2,207,000 |
| Debt Issued | N/A | N/A | 5,024,000 | 3,038,000 | 3,039,000 |
| Debt Repayment | -1,982,000 | -1,762,000 | -2,213,000 | -1,184,000 | -1,154,000 |
| Common Stock Issued | 13,000 | 2,000 | 14,000 | 24,000 | 19,000 |
| Common Stock Repurchased | -497,000 | -200,000 | -1,161,000 | -667,000 | -667,000 |
| Dividend Paid | -549,000 | -281,000 | -855,000 | -641,000 | -404,000 |
| Other Financing Activity | 2,000 | 1,000 | 5,000 | 0 | 0 |
| Financing Cash Flow | $-3,008,000 | $-2,260,000 | $-1,678,000 | $-1,944,000 | $-1,374,000 |
| Exchange Rate Effect | -71,000 | -61,000 | 23,000 | 10,000 | -5,000 |
| Beginning Cash Position | 2,879,000 | 2,879,000 | 1,096,000 | 1,096,000 | 1,096,000 |
| End Cash Position | 1,245,000 | 1,394,000 | 2,879,000 | 1,432,000 | 1,188,000 |
| Net Cash Flow | $-1,634,000 | $-1,485,000 | $1,783,000 | $336,000 | $92,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 1,977,000 | 1,102,000 | 4,572,000 | 2,995,000 | 1,947,000 |
| Capital Expenditure | -489,000 | -264,000 | -1,104,000 | -777,000 | -528,000 |
| Free Cash Flow | 1,488,000 | 838,000 | 3,468,000 | 2,218,000 | 1,419,000 |